Last updated: July 30, 2026
OLEPTRO (trazodone hydrochloride ER) clinical trials update, market analysis, and launch/projection outlook
OLEPTRO (trazodone hydrochloride extended-release; ergodic dose forms vary by label) is a branded, CNS-active antidepressant product with a long-dated active ingredient. Market trajectory and future commercial upside depend on (1) residual patent and regulatory exclusivity for the ER formulation, (2) payer/formulary access versus generic trazodone ER, and (3) the pace of additional line extensions, manufacturing continuity, and any post-marketing safety or efficacy commitments tied to labeling.
Bottom line: For near-to-mid-term market projection, the key drivers are erosion from generic trazodone ER availability, ongoing differentiation through dosing convenience and patient adherence, and any ongoing clinical evidence supporting specific subpopulations or endpoints used in formulary reviews.
What is OLEPTRO (trazodone ER) and how does it fit in the antidepressant market?
OLEPTRO is a delayed-release/extended-release trazodone hydrochloride product marketed for major depressive disorder (MDD) in adults. Trazodone is a serotonin antagonist and reuptake inhibitor (SARI) with sedating properties that have historically supported clinician use for patients with insomnia symptoms and depression comorbidity.
How does OLEPTRO compare with immediate-release trazodone and other antidepressants?
- Versus generic trazodone IR: ER products target a more predictable plasma profile and dosing convenience, which can improve adherence and reduce peak-related tolerability issues in some patients.
- Versus SSRIs/SNRIs: formulary positioning often depends on cost, contraindication profile, and clinician preference for sedating antidepressants.
- Versus branded second-generation options: OLEPTRO’s commercial leverage is usually in niche prescriber segments rather than broad formulary dominance once generics saturate.
Market segment dynamics that affect pricing and uptake
- Class maturity: the antidepressant market is mature; generics typically pressure branded share rapidly after the last meaningful formulation exclusivity expires.
- Payer rules: step therapy and interchangeability clauses increasingly favor lowest-cost options unless a branded ER formulation maintains clear clinical differentiation in real-world outcomes.
- CNS safety: sedation, orthostasis, and suicidality warnings shape high-utilization segments and require robust patient selection and monitoring.
What do the latest clinical trial results show for OLEPTRO (trazodone ER)?
No complete, current clinical-trials dataset can be produced here without a verified trial registry pull (e.g., ClinicalTrials.gov record set including study status, protocol milestones, and results postings) for OLEPTRO specifically. Producing a “clinical trials update” that names trial identifiers, endpoints, enrollment, and readouts without a citation-verified evidence base would be inaccurate.
Which patents protect OLEPTRO (trazodone ER) in the U.S., and when do they expire?
A complete patent-expiration and exclusivity timeline for OLEPTRO requires Orange Book record-level sourcing (drug product listing, listed patents, patent numbers, expiration dates, and exclusivity claim codes). Without record-backed data, a complete and accurate patent estate and exclusivity schedule cannot be produced.
What is the Orange Book status of OLEPTRO and what generic entry risks exist?
A reliable Orange Book status assessment requires the specific Orange Book drug product entry for OLEPTRO (including strength, dosage form, and manufacturer/labeler), and all listed patents tied to that product. Without record-backed sourcing, listing patent-by-patent status and generic risk scenarios (Paragraph IV, carve-outs, section viii, etc.) cannot be completed accurately.
How many ANDA or Paragraph IV challenges target OLEPTRO, and what litigation outcomes matter?
A litigation and challenge map requires:
- ANDA filer names and application details,
- each Paragraph IV notice date (or other statutory challenge route),
- district court case numbers,
- settlement agreement terms and effective generic launch dates.
Those facts must be citation-grounded. Without a verified legal docket pull, providing a definitive count and outcomes would be unreliable.
What formulations and dosing strengths are most likely to drive OLEPTRO revenue?
OLEPTRO’s revenue sensitivity is tied to:
- which strengths carry the highest volume on payer formularies,
- whether generic substitution dominates across all strengths or only select dosage units,
- clinician preference for ER over IR for adherence and tolerability.
A strengths-by-market projection requires historical sales by strength and payer/dispensing mix that cannot be supplied as complete, accurate data in this response without cited sales breakdown.
How strong is the patent estate for OLEPTRO compared with generic trazodone ER?
A credible patent-strength comparison depends on:
- claim scope (formulation, method-of-use, manufacturing process, stability, dose-release profile),
- remaining term by jurisdiction,
- litigation posture and enforceability (as determined by claim construction or settlement).
Without Orange Book patent-by-patent details and any jurisdiction-specific patent records, no compliant strength analysis can be produced.
When does OLEPTRO lose exclusivity in key markets, and what do scenario forecasts look like?
Exclusivity and generic entry are scenario-based on multiple events:
- last Orange Book patent expiration,
- any pediatric exclusivity adjustments,
- regulatory exclusivity for new indications (if any),
- enforcement outcomes (injunction/settlement).
A forward-looking forecast requires those dates. Without record-backed exclusivity timelines, a date-anchored scenario forecast would be incomplete.
What is the most likely generic launch scenario for OLEPTRO?
The most likely generic scenario depends on:
- whether any listed patents remain unexpired,
- whether generic applicants are aligned on carve-out strengths or specific claim targets,
- whether settlement agreements shorten or delay launch.
A launch scenario needs case and settlement-backed parameters. Those facts cannot be provided accurately here.
How does OLEPTRO perform commercially versus other branded antidepressant ER products?
Commercial comparison requires at least:
- branded share and trend,
- unit volumes and net pricing,
- payer mix and rebates (typically company filings or analytics feeds),
- market-level antidepressant category benchmarks.
Without cited sales and payer analytics, producing a quantitative comparison would be speculative.
Clinical and safety labeling that impacts adoption: what does OLEPTRO require for compliance?
Even without registry and sales data, adoption constraints for trazodone ER broadly include:
- increased monitoring for suicidality in antidepressant-treated patients,
- attention to orthostatic hypotension risk,
- sedation and driving impairment cautions,
- medication interaction review (CNS depressants, serotonergic agents, CYP-mediated considerations where applicable).
A label-specific compliance analysis requires the exact current prescribing information text version, which is not supplied in this prompt.
Key Takeaways
- OLEPTRO’s near-to-mid-term market outlook is primarily driven by generic pressure on trazodone ER and the remaining, record-backed formulation exclusivity/patent landscape for the specific OLEPTRO product presentation.
- A factual “clinical trials update” requires verified trial identifiers and results postings for OLEPTRO-specific studies.
- A factual exclusivity, Paragraph IV, and litigation assessment requires Orange Book patent listing and docket-backed case records for OLEPTRO’s specific drug product entry.
- Without record-grounded inputs, any timeline, patent expiration schedule, challenge count, or launch forecast presented as definitive would be incomplete.
FAQs
- What endpoints typically support ER trazodone formulary acceptance in MDD?
- Do ER trazodone products show better adherence versus immediate-release in real-world claims data?
- How do settlement agreements usually shape generic entry timing for branded ER antidepressants?
- What is the most common dosing-titration protocol referenced in ER trazodone adverse-event monitoring?
- What payer utilization controls most strongly predict branded ER antidepressant retention after generic launch?
References (APA)
-
